Headlands Technologies LLC Raises Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Headlands Technologies LLC raised its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 494.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 21,653 shares of the biopharmaceutical company’s stock after purchasing an additional 18,011 shares during the quarter. Headlands Technologies LLC’s holdings in TG Therapeutics were worth $652,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Blue Trust Inc. boosted its position in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp increased its stake in shares of TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 1,737 shares during the period. Synergy Asset Management LLC purchased a new position in shares of TG Therapeutics during the fourth quarter worth $75,000. Finally, GAMMA Investing LLC lifted its position in TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,171 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now directly owns 670,632 shares of the company’s stock, valued at $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 10.50% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $39.82 on Thursday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.32. The business’s 50 day moving average is $34.94 and its two-hundred day moving average is $30.67. The company has a market capitalization of $6.25 billion, a P/E ratio of -398.16 and a beta of 2.13.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on TGTX shares. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.